



Special Endocrine Testing

Effective Date: May 25, 2016

Scope

This guideline provides recommendations on the appropriate indications for testing of selected endocrine hormones in patients aged ≥ 19 years, mainly in a primary health care setting. The document is intended to provide direction to primary care physicians and help constrain inappropriate test utilization particularly as it pertains to so-called wellness and “anti-aging” practices. However, it does not represent exhaustive guidance to the appropriate use of the endocrine tests listed as other indications will be identified in the practices of RCPSC certified gynecologists, urologists, laboratory physicians, and endocrinologists. The document is not intended to address the care of pediatric or transgender patients.

A few of the lab tests mentioned in this guideline may be less than familiar to some practitioners, but their inclusion is intentional. A goal of completeness required listing all routinely available tests potentially relevant to a given endocrine condition. Additionally, the working group recognized that practitioners routinely vary in their chosen clinical interests, and that some may wish to pursue investigations for some conditions to a greater degree than would their colleagues. Finally, inclusion of some lesser known tests hopefully serves to refine and advance the continuing medical education of all interested guideline readers.

Key Recommendations

- Testosterone testing in women for the investigation of low libido is not useful.
 - Estradiol testing in men is not useful unless there are signs of spontaneous feminization.
 - 1,25(OH)₂ Vitamin D testing, with rare exception, is indicated for the investigation of hypercalcemia with concomitantly low parathyroid hormone (PTH) only and is not indicated for monitoring patients receiving calcitriol.
 - Insulin testing is primarily useful for investigation of spontaneous hypoglycemia or to help distinguish type I diabetes from type II diabetes, but not for establishment of insulin resistance.
 - The utility of salivary hormone testing in any clinical context is limited to Cushing Syndrome screening using late night salivary cortisol levels.
 - Screening for growth hormone (GH) related disorders with insulin-like growth factor 1 (IGF1) is only indicated in patients demonstrating symptoms of GH excess (acromegaly) or deficiency.
-

Testing

1. Reproduction				
Including: Testosterone – Total; Sex Hormone Binding Globulin; Estradiol; Progesterone; Luteinizing Hormone; Follicle Stimulating Hormone; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone-sulphate; 17-hydroxyprogesterone; Prolactin.				
Test*	Indications		Non-Indications	Notes
	Male	Female		
Testosterone – Total ^{1–10} (T) \$15.81 For information about Free Testosterone and Bioavailable Testosterone , see <i>Appendix A: Testosterone Testing and Measurements in BC</i> .	Investigation of male hypogonadism. Monitoring of males receiving androgen replacement. Confirming adequacy of anti-androgen therapy in males with prostate carcinoma.	Investigation of female androgen excess.	Screening for biochemical evidence of hypogonadism is not indicated in males without symptoms. Some symptoms of hypogonadism overlap with normal effects of aging. ³ Not useful for investigation of decreased libido in females. ⁷ Not useful for monitoring females receiving androgen therapy for low libido unless overuse is suspected or unexpected virilization has developed.	For the investigation of male hypogonadism. Diurnal variation of T requires that collection be performed between 7 and 10 am or within 3 hours of waking. Only tandem mass spectrometry is sufficiently sensitive to accurately measure the low total testosterone seen in normal females or males rendered chemically castrate for prostate carcinoma. For information, refer to BCGuidelines.ca : <i>Testosterone Testing Protocol</i> .
Sex Hormone Binding Globulin (SHBG) \$13.56	Clarification of borderline low total testosterone. Investigation of males with high testosterone of endogenous origin.	Clarification of borderline high total testosterone results.		Total testosterone is the first-line test for male hypogonadism.
Estradiol ² (E2) \$22.43	Not indicated in routine clinical practice. Investigation for estrogen producing neoplasms in males demonstrating spontaneous feminization including gynecomastia.	Investigation of primary ovarian insufficiency or infertility. Investigation of primary ovarian insufficiency—where possible, order in conjunction with FSH on day 3 of menstrual cycle (not day 21). Monitoring of patients receiving aromatase inhibitor therapy. Detection of estrogen-producing neoplasms. For monitoring of females undergoing fertility treatment.	Not indicated in the investigation of male osteoporosis. ¹¹ Not indicated for monitoring of men receiving testosterone therapy. ¹² Not indicated to determine if a woman is in menopause except in those with prior hysterectomy without bilateral salpingo-oophrectomy. Not indicated for monitoring of patients receiving ERT.	E2 immunoassay performance is poor at low concentration ^{2, 13} ranges making these assays inadequate for use in females receiving aromatase inhibitors ¹⁴ and in most male patients. E2 analysis by tandem mass spectrometry can be arranged for females receiving aromatase inhibitors. For the investigations of female osteoporosis, see BCGuidelines.ca : <i>Osteoporosis: Diagnosis, Treatment and Fracture Prevention</i> .
Progesterone \$14.86	Not indicated.	Investigation of infertility. Identification of prior ovulation. Investigation of pregnancy viability. ¹⁵	Not indicated to determine if a woman is in menopause except in those with prior hysterectomy without bilateral salpingo-oophrectomy.	Fertility measurement is made at day 21 or mid-luteal phase.

Test*	Indications		Non-Indications	Notes
	Male	Female		
Luteinizing Hormone ^{16, 17} (LH) \$12.41	Investigation of primary or secondary hypogonadism.	Investigation of primary or secondary hypogonadism. Investigation of infertility. Prediction of ovulation (by LH surge).	LH / FSH ratio is not recommended to identify women with PCOS but has clinical value in established cases. ¹⁸ Not indicated to determine if a woman is in menopause except in those with prior hysterectomy without bilateral salpingo-oophrectomy.	Usually performed in combination with measurement of appropriate sex steroids (T for males, E2 for females).
Follicle Stimulating Hormone ^{16, 17} (FSH) \$13.13	Investigation of primary or secondary hypogonadism. Investigation of oligospermia or azoospermia.	Investigation of primary or secondary hypogonadism. Investigation of infertility. Investigation of primary ovarian insufficiency or infertility—where possible, order in conjunction with E2 on day 3 of menstrual cycle.	LH / FSH ratio is not recommended to identify women with PCOS but has clinical value in established cases. ¹⁸ Not indicated to determine if a woman is in menopause except in those with prior hysterectomy without bilateral salpingo-oophrectomy.	Usually performed in combination with measurement of appropriate sex steroids (T for males, E2 for females).
Androstenedione \$36.09	Not indicated in routine clinical practice. May be useful in monitoring therapy in patients with established CAH. ¹⁹	Not indicated in routine clinical practice. Functions as a second-line tool in the investigation of PCOS often in specialty practice. May be useful in monitoring therapy in patients with established CAH. ¹⁹	Not indicated in the investigation of male hypogonadism as this is primarily an adrenal steroid.	
Dehydroepiandrosterone (DHEA) \$18.55	Not indicated.	Not indicated.	Not indicated in the investigation of male hypogonadism as this is an adrenal steroid.	
Dehydroepiandrosterone –sulphate ²⁰ (DHEA-S) \$18.55	Not indicated in routine clinical practice. Investigation of adrenal mass.	Investigation of PCOS. Investigation of adrenal mass.	Not useful for the investigation of male hypogonadism as this is an adrenal steroid.	
17-hydroxyprogesterone (17-OHP) \$41.71	Not indicated in routine clinical practice.	For the diagnosis of non-classic CAH as a cause of hirsutism and for monitoring of CAH therapy.		
Prolactin \$13.49	Investigation of infertility / hypogonadism /amenorrhea. Investigation of galactorrhea. Investigation for prolactinoma and other pituitary tumours. Monitoring of prolactinoma in patients treated medically or surgically.		Not useful for monitoring pregnant or lactating patients.	

2. Calcium and Bone Metabolism

Including: 25-hydroxyvitamin D; 1,25 dihydroxyvitamin D; Parathyroid Hormone

25-hydroxyvitamin D (25(OH)D) \$61.32	Investigation of vitamin D nutritional status only by specialists in clinical scenarios where biochemical identification of vitamin D deficiency is necessary.	Not useful in the investigation of hypercalcemia unless there is clinical suspicion of vitamin D supplement overdose.	If ordered by a family physician, the patient must pay for analysis. For information, refer to BCGuidelines.ca : <i>Vitamin D Testing Protocol</i> .
1,25 dihydroxyvitamin D (1,25(OH)2D) \$94.49	Investigation of hypercalcemia with concomitantly low PTH.	Should not be used for the investigation of vitamin D nutritional status. Should not be used to monitor levels of pharmacologically administered calcitriol.	
Parathyroid Hormone (PTH) \$17.52	Investigation of hyper and hypocalcemia. Monitoring and treatment of renal osteodystrophy.		In patients with previously identified hypo or hypercalcemia, measure concomitantly with a repeat total or ionized calcium.

3. Adrenal

Including: Aldosterone (Plasma and Urine); Renin; Cortisol (24-hour urine free); Cortisol (serum/plasma); Cortisol (late night salivary); Adrenocorticotrophic hormone stimulation test; Adrenocorticotrophic; 24-hour urinary excretion of catecholamines and metanephrines; Plasma Catecholamines; Plasma Free Metanephrine

Test*	Indications	Non-Indications	Notes
Aldosterone, Plasma and Urine \$170.92	Investigation of secondary causes of hypertension: primary aldosteronism, renal artery stenosis.	Not indicated for the initial investigation of syncope or hypotension caused by possible adrenal insufficiency. For adrenal insufficiency, screen with am cortisol and proceed to 250 µg ACTH stimulation test as indicated.	For ambulatory patients meeting criteria for primary aldosteronism screening, order upright plasma aldosterone and plasma renin activity after 1–2 hours ambulation and before 10 am. ²¹ Numerous physiological states and medications interfere with sensitivity and specificity of screening. ²¹
Renin \$63.87 – \$98.11	Investigation of secondary causes of hypertension: primary aldosteronism and renal artery stenosis. Monitoring of CAH and mineralocorticoid supplementation in Addison's Disease.		
Cortisol, 24-hour urine free	Used for targeted screening for Cushing Syndrome caused by endogenous cortisol excess only.	Not useful for the diagnosis of Addison's Disease. Do not order in patients receiving exogenous glucocorticoids.	Numerous studies have found males to have higher excretion rates than females. Application of sex specific reference intervals advised in cases where elevation is equivocal. ^{22, 23}

Test*	Indications	Non-Indications	Notes
Cortisol, serum/plasma \$13.28	Used in the targeted screening and diagnosis of both Addison's Disease (primary adrenal insufficiency) and Cushing Syndrome.	Not useful in the investigation of non-specific fatigue and lethargy unless accompanied by clinical syndromes of Addison's Disease or Cushing Syndrome. Measurement of morning and afternoon cortisol (for diurnal variation) is not useful.	A morning cortisol measurement can be used to exclude adrenal insufficiency. Collect sample between 7 am and 10 am or within 3 hours of waking. Do not order random cortisol levels for this purpose. An am serum/plasma cortisol is not useful as a screen for Cushing Syndrome. Use 1 mg overnight dexamethasone suppression, 24-hour urinary free cortisol or late night salivary cortisol. ^{24,25} For cortisol analysis after ACTH stimulation, see adrenocorticotrophic hormone simulation test. Measurement of cortisol in patients being treated with exogenous glucocorticoids presents numerous bioanalytical and interpretive challenges and is not advised without consultation with an endocrinologists and/or laboratory physician/scientist.
Cortisol, late night salivary \$77.25	Used to screen for Cushing Syndrome caused by endogenous cortisol excess only.		Only available through Vancouver General Hospital. Measurement of cortisol in patients being treated with exogenous glucocorticoids presents numerous bioanalytical and interpretive challenges and is not advised without consultation with an endocrinologists and/or laboratory physician/scientist.
Adrenocorticotrophic hormone stimulation test (ACTH stimulation test) \$45.24	Used in the diagnosis of Addison's Disease (primary adrenal insufficiency) and secondary adrenal insufficiency. Used in the diagnosis of non-classic CAH.		Patients with Addison's Disease have marked elevations of plasma ACTH at initial presentation provided that they are not exposed to exogenous glucocorticoid. 17-OHP is also ordered if non-classic CAH is a diagnostic consideration. Measurement of cortisol in patients being treated with exogenous glucocorticoids presents numerous bioanalytical and interpretive challenges and is not advised without consultation with an endocrinologists and/or laboratory physician/scientist.
Adrenocorticotrophic (ACTH) \$36.57	Used in the diagnosis Addison's Disease (primary adrenal insufficiency) and secondary adrenal insufficiency. Used to distinguish between Cushing Syndrome caused by adrenal adenoma and Cushing Syndrome caused by inappropriate ACTH production from pituitary adenoma or ectopic source. Used in the diagnosis of non-classic CAH.		For the investigation of adrenal insufficiency, concomitant am ACTH and cortisol should be performed before pursuit of ACTH stimulation testing.

Test*	Indications	Non-Indications	Notes
24-hour urinary excretion of catecholamines and metanephrines \$46.45 catecholamines \$155.77 metanephrines	Used in the diagnosis of pheochromocytoma and functional paraganglioma.	Urinary vanillylmandelic acid, although the end metabolite of both epinephrine and norepinephrine, has test characteristics inferior to urinary catecholamines and metanephrines and is not required for the investigation of pheochromocytoma. ²⁶ Urinary dopamine and homovanillic acid are not required for the initial investigation of pheochromocytoma. This test is not to be used as a tool for psychiatric assessment.	This test is subject to false positives from physiological stressors, certain foods, and numerous medications. Appropriate patient preparation is required to yield meaningful results. ^{27,28}
Plasma Catecholamines \$59.27	Of limited use in the diagnosis of pheochromocytoma and functional paraganglioma.	This test is not to be used as a tool for psychiatric assessment.	This test is very sensitive to stress-related fluctuations during collection and requires an indwelling catheter, supine posture and a calm environment to generate useful results.
Plasma Free Metanephrines \$N/A	Used in the diagnosis of pheochromocytoma and functional paraganglioma.	This test is not to be used as a tool for psychiatric assessment.	Not currently offered in BC. Can be arranged as an out of province send-out where required (e.g., for diagnostic clarity in ambiguous cases or for the oliguric patient). This test is sensitive to patient posture and supine collections are recommended. ²⁷
4. Thyroid			
Including: Thyroid Stimulating Hormone; Free Thyroxine; Free Triiodothyronine; Total thyroxine/ triiodothyronine; Anti-thyroid peroxidase; Thyroglobulin/ Antithyroglobulin; Antibodies to the thyroid stimulating hormone receptor			
Thyroid Stimulating Hormone (TSH) \$9.90	Used to screen for all causes of primary hypothyroidism and hyperthyroidism. Monitoring of patients treated with thyroid hormone.		TSH may be repeated after at least 6–12 weeks following a change in thyroid hormone replacement dose or after a change in a patient's clinical status. TSH monitoring in pregnancy can be as frequent as every 4–6 weeks. ²⁹ Once the TSH has normalized with treatment, it should be checked annually unless clinically indicated. For information, refer to BCGuidelines.ca : <i>Thyroid Function Tests: Diagnoses and Monitoring of Thyroid Function Disorders in Adults</i> .
Free Thyroxine (fT4) \$12.12	Used for diagnostic confirmation of hyper/hypothyroidism when TSH is abnormal. Used to assess the severity of hyperthyroidism and ongoing management of Graves' Disease and other forms of hyperthyroidism. Used to monitor T4 supplementation in patients with secondary hypothyroidism (pituitary cause).	Not for use in an initial screen for thyroid dysfunction except in the unusual circumstance that there is specific reason to suspect pituitary disease.	

Test*	Indications	Non-Indications	Notes
Free Triiodothyronine (fT3) \$9.35	Rarely indicated. Reserved for situations where hyperthyroidism is suspected clinically and TSH is suppressed, but fT4 is not elevated.	Not for use in an initial screen for thyroid dysfunction.	
Total thyroxine/triiodothyronine (Total T4/T3)	Not currently offered by any lab in BC. Replaced by free hormone determination.		
Anti-thyroid peroxidase \$20.22	Used for the diagnosis of Hashimoto's thyroiditis in the investigation of primary hypothyroidism.	Serial measurements are not indicated.	
Thyroglobulin/Antithyroglobulin (Tg/Anti Tg) \$27.90/\$20.40	Serves as a tumor marker for patients who have undergone previous treatment for papillary or follicular thyroid carcinoma.	Anti-Tg measurements are not indicated for the investigation for general thyroid autoimmunity. Tg measurement is not indicated in patients with an intact thyroid except in rare circumstances.	Anti-Tg must be measured concomitantly with Tg as the presence of Anti-Tg makes Tg results unreliable.
Antibodies to the thyroid stimulating hormone receptor (TRAb) \$22.48	Used for the diagnosis of Graves' Disease. In certain clinical scenarios TRAb testing may be used as a first-line tool to distinguish Graves' Disease from other forms of hyperthyroidism. See notes.	Not indicated for the investigation for general thyroid autoimmunity.	Although radioactive iodine uptake remains the gold standard for the identification of hyperthyroidism caused Graves' Disease, TRAb offers advantages in specific clinical scenarios: investigation of unilateral exophthalmos, euthyroid Graves ophthalmopathy, diagnosis of Graves' Disease where exposure to radioactive iodine is contraindicated (pregnancy) or where the patient is apprehensive about exposure to radiotracers. TRAb also serves as a prognostic tool in a number of clinical scenarios. ^{30,31} TRAb testing is more easily arranged and results are typically available sooner than radioactive iodine uptake and scan.
5. Growth			
Including: Growth Hormone; Insulin-like Growth Factor 1			
Growth Hormone (GH) \$30.38	Used to confirm diagnosis and to assess response to treatment in acromegaly by use of dynamic function tests. Used to assess pituitary ability to generate GH in dynamic function tests for hypopituitarism or pituitary growth hormone deficiency.	A random GH should not be ordered to screen for the investigation of either acromegaly or GH deficiency.	
Insulin-like Growth Factor 1 (IGF1) \$55.08	Used to screen for acromegaly and growth hormone deficiency in symptomatic patients. Used for the monitoring response to treatment (surgical or medical) for acromegaly. Used to monitor response to therapy in patients receiving recombinant GH.	Should not be ordered unless there are specific symptoms of acromegaly or evidence/risk factors for hypopituitarism. ³²	Reference intervals are highly dependent on age. Please use age-specific reference interval provided on the lab report. A complete chart of reference intervals by age is available from St. Paul's Hospital Department of Pathology and Laboratory Medicine website. www.providencelaboratory.com/cmsUploads/CAP/File/06-Mar-2013_IGF1_Technical.pdf

6. Glucose Homeostasis

Including: Insulin; C-peptide

Test*	Indications	Non-Indications	Notes
Insulin <div style="text-align: right;">\$27.55</div>	Investigation of hypoglycemia. Note that the specimen collected at the time of hypoglycemia must be analyzed. Fasting insulin may be useful in the investigation of PCOS in females. ³³	Not indicated for patients receiving insulin therapy. Not for the investigation of impaired fasting glucose or the establishment of insulin resistance. Lack of standardization in insulin assays and lack of data for normative responses mean that glucose-stimulated insulin measurements are not recommended in clinical practice. ^{34, 35}	Reference intervals are BMI-dependent and require fasting state. May be helpful in distinguishing type 1 from type 2 diabetics in equivocal cases, prior to commencement of therapy. For investigation of hypoglycemia, the specimen demonstrating hypoglycemia is required and must be frozen at the earliest possible opportunity. Occasionally confirmation of surreptitious or accidental insulin administration is clinically indicated in cases of hypoglycemia. However, many insulin assays do not detect synthetic analog insulins well. Specialized analysis is required to detect synthetic analogues. Consult with laboratory physician or scientist for advice.
C-peptide <div style="text-align: right;">\$47.42</div>	Investigation of hypoglycemia.		Reference intervals are BMI-dependent and require fasting state. May be helpful in distinguishing type 1 from type 2 diabetics in equivocal cases, prior to commencement of therapy. C-peptide clearance is poor in patients with CKD, where large elevations above the reference interval are common.

Abbreviations: 1,25(OH)₂D = 1,25 dihydroxyvitamin D; 17-OHP = 17-hydroxyprogesterone; 25(OH)D = 25-hydroxyvitamin D; ACTH = adrenocorticotrophic hormone; Anti-TPO = Anti-thyroid peroxidase; BMI = body mass index; CAH = congenital adrenal hyperplasia; CKD = chronic kidney disease; DHEA = dehydroepiandrosterone; DHEA-S = dehydroepiandrosterone-sulphate; E2 = estradiol; ERT = estrogen replacement therapy; FSH = follicle stimulating hormone; fT3 = free triiodothyronine; fT4 = free thyroxine; GH = growth hormone; h = hour; IGF1 = insulin-like growth factor 1; LH = luteinizing hormone; PCOS = polycystic ovary syndrome; SHBG = sex hormone binding globulin; T = testosterone-total; T4 = thyroxine; T3 = triiodothyronine; Tg = thyroglobin; TRAb = TSH Receptor Antibody; TSH = thyroid stimulating hormone.

Note: *Includes the Fee-for-Service costs as per the Schedule of Fees – Laboratory Services Payment Schedule, as of October 1, 2015.

► References

1. Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. *J Clin Endocrinol Metab*. 2007;92(2):405-13.
2. Vesper HW, Botelho JC, Wang Y. Challenges and improvements in testosterone and estradiol testing. *Asian J Androl*. 2014;16(2):178-84.
3. Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. *CMAJ*. 2015; 187(18):1369-1377.
4. Paduch DA, Brannigan RE, Fuchs EF, et al. The laboratory diagnosis of testosterone deficiency. *Urology*. 2014;83(5):980.
5. Davis SR, Davison SL, Donath S, et al. Circulating androgen levels and self-reported sexual function in women. *JAMA*. 2005;294(1):91-6.
6. Basson R, Brotto LA, Petkau AJ, et al. Role of androgens in women's sexual dysfunction. *Menopause*. 2010;17(5):962-71.
7. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2014;99(10):3489-510.
8. Yun YM, Botelho JC, Chandler DW, et al. Performance criteria for testosterone measurements based on biological variation in adult males: recommendations from the Partnership for the Accurate Testing of Hormones. *Clinical chemistry*. 2012;58(12):1703-10.
9. Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography–mass spectrometry in sera from 116 men, women, and children. *Clinical chemistry*. 2003;49(8):1381-95.
10. Wang C, Catlin DH, Demers LM, et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography–tandem mass spectrometry. *J Clin Endocrinol Metab*. 2004;89(2):534-43.
11. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2012;97(6):1802-22.
12. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2010 Jun;95(6):2536-59.
13. Rosner W, Hankinson SE, Sluss PM, et al. Challenges to the measurement of estradiol: an endocrine society position statement. *J Clin Endocrinol Metab*. 2013 Mar 5;98(4):1376-87.
14. Folkerd EJ, Lønning PE, Dowsett M. Interpreting plasma estrogen levels in breast cancer: caution needed. *JOC*. 2014;32(14):1396-1400.
15. Canavan TP, Mastrobattista JM. First-Trimester Ultrasound: Early Pregnancy Failure. In: *First-Trimester Ultrasound 2016* (pp. 253-282). Springer International Publishing.
16. Legro SA, Arslanian DA, Ehrmann KM, et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2013; 98(12):4565–4592.
17. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. *Eur J Endocrinol*. 2014;171(4):P1–29.
18. Cho LW, Jayagopal V, Kilpatrick ES, et al. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. *Annals of clinical biochemistry*. 2006 May 1;43(3):217-9.
19. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2010 Sep;95(9):4133-60.
20. Allolio B, Fassnacht M. Adrenocortical carcinoma: Clinical Update. *J Clin Endocrinol Metab*. 2006, 91(6):2027–2037.
21. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2016 Mar 2;jc-20154061[Epub ahead of print].
22. Murphy BE. Urinary free cortisol determinations: what they measure. *The Endocrinologist*. 2002;12(2):143-50.
23. Kushnir MM, Rockwood AL, Nelson GJ, et al. Liquid chromatography–tandem mass spectrometry analysis of urinary free cortisol. *Clinical chemistry*. 2003 Jun 1;49(6):965-7.
24. Carroll TB, Findling JW. The diagnosis of Cushing's syndrome. *Reviews in Endocrine and Metabolic Disorders*. 2010;11(2):147-53.
25. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2008;93(5):1526-40.
26. Boyle JG, Davidson DF, Perry CG, et al. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. *J Clin Endocrinol Metab*. 2007;92(12):4602-8.
27. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2014;99(6):1915-42.
28. van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. *Eur J Endocrinol*. 2014;170(3):R109-19.
29. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2012 Aug;97(8):2543-65.
30. Matthews DC, Syed AA. The role of TSH receptor antibodies in the management of Graves' disease. *Eur J Intern Med*. 201;22(3):213-6.
31. Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. *J Clin Endocrinol Metab*. 2013;98(6):2247.
32. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2014; 99(11):3933–3951.
33. Traub ML. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. *World J Diabetes*. 2011;2(3):33-40.
34. Buchanan TA, Watanabe RM, Xiang AH. Limitations in surrogate measures of insulin resistance. *T J Clin Endocrinol Metab*. 2010;95(11):4874-6.
35. Antuna-Puente B, Disse E, Rabasa-Lhoret R, et al. How can we measure insulin sensitivity/resistance?. *Diabetes & metabolism*. 2011;37(3):179-88.

► Appendices

- Appendix A: Testosterone Testing and Measurements in BC

► Associated Documents

The following documents accompany this guideline:

- [BCGuidelines.ca: Testosterone Testing Protocol](#)
- [BCGuidelines.ca: Osteoporosis: Diagnosis, Treatment and Fracture Prevention](#)
- [BCGuidelines.ca: Vitamin D Testing Protocol](#)
- [BCGuidelines.ca: Thyroid Function Tests: Diagnoses and Monitoring of Thyroid Function Disorders in Adults](#)

This guideline is based on scientific evidence current as of the Effective Date.

This guideline was developed by the Guidelines and Protocols Advisory Committee, approved by the British Columbia Medical Association, and adopted by the Medical Services Commission.

THE GUIDELINES AND PROTOCOLS ADVISORY COMMITTEE

The principles of the Guidelines and Protocols Advisory Committee are to:

- encourage appropriate responses to common medical situations
- recommend actions that are sufficient and efficient, neither excessive nor deficient
- permit exceptions when justified by clinical circumstances

Contact Information:

Guidelines and Protocols Advisory Committee
PO Box 9642 STN PROV GOVT
Victoria BC V8W 9P1
Email: hlth.guidelines@gov.bc.ca
Website: www.BCGuidelines.ca

Disclaimer

The Clinical Practice Guidelines (the “Guidelines”) have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give an understanding of a clinical problem, and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problem. **We cannot respond to patients or patient advocates requesting advice on issues related to medical conditions. If you need medical advice, please contact a health care professional.**



Appendix A: Testosterone Testing and Measurements in BC

Testosterone exists in multiple compartments in the patient plasma. Owing to its non-polar chemical structure, only a very small fraction of testosterone is freely dissolved and this is the biologically active fraction. Testosterone is also heavily bound to two plasma proteins: (1) albumin which is high-capacity (i.e., high in concentration) and low-affinity (i.e., loosely binding) and (2) sex hormone binding globulin (SHBG) which is low-capacity (low in concentration) and high-affinity (avidly binding). Partridge¹ hypothesized that both the albumin-bound and the free testosterone were relatively biologically available compared to the SHBG-bound testosterone. He popularized the measurement of so-called “bioavailable testosterone” which is the sum of the free and albumin-bound fractions of testosterone. With these definitions in mind, testosterone can be measured as follows:

Total Testosterone: The sum of all testosterone fractions in the patient plasma, whether free or protein-bound. In BC this is routinely measured by automated immunoassay at most labs and by tandem mass spectrometry at St. Paul’s Hospital.

Bioavailable Testosterone: The sum of free testosterone and albumin bound testosterone. This can be measured by selectively precipitating SHBG and performing a total testosterone assay on the remaining solution (“supernatant”). Due to poor repeatability, this method is no longer employed in BC. Alternatively, bioavailable testosterone can be calculated from the total testosterone, SHBG and albumin concentrations using one of a number of formulas,² most often Vermeulen’s equation.³ Calculating bioavailable testosterone is probably a superior approach to the method of selective precipitation but is hampered by the fact that different kits for measuring total testosterone and SHBG produce different numerical results on the same patient sample. This leads to poor inter-laboratory comparability for this test. Consequently each lab must generate reference intervals specific to their methods for total testosterone and SHBG. Given the fact that free and bioavailable testosterone demonstrate more age-dependence in older males than total testosterone,^{4,5} a large number of subjects is required to accomplish this.

Free Testosterone: This is the testosterone that is freely dissolved in the patient plasma. In BC, this is performed by measuring total testosterone, SHBG, and albumin and then calculating the free testosterone in the same manner as the bioavailable testosterone is determined.² Calculated free testosterone is essentially a constant multiple of calculated bioavailable testosterone and neither offers any advantage over the other if both reference ranges are identically validated. In extenuating circumstances, free testosterone can be measured by a reference method using equilibrium-dialysis followed tandem mass spectrometry. This is not offered in Canada at the present time. Methods for free testosterone by analogue-based radioimmunoassay perform so poorly that they have been discontinued in BC and elsewhere.^{6,7,8}

Salivary Testosterone: Saliva offers an ultrafiltrate of the plasma and therefore salivary testosterone correlates with free testosterone in both men and women.^{9,10} However, tandem mass spectrometry is required to accurately quantify testosterone at the low levels seen in saliva (down to 0.005 nmol/L for women). This assay is not currently offered at any Canadian reference laboratory. However, results depend on the manner in which saliva is collected and are not clinically equivalent to free testosterone.¹⁰ For this reason, salivary testosterone is, at present, a research-level tool we do not recommend incorporating it into routine clinical practice.

► References

1. Manni A, Partridge WM, Cefalu W, et al. 1985 Bioavailability of albumin bound testosterone. *J Clin Endocrinol Metab.* 61:705–710.
2. De Ronde W, Van der Schouw YT, Pols HA, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. *Clinical chemistry.* 2006;52(9):1777–84.
3. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab.* 1999;84(10):3666–72.
4. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. *J Clin Endocrinol Metab.* 2011;96(8):2430–9.

5. Mohr BA, Guay AT, O'Donnell AB, et al. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. *Clinical endocrinology*. 2005;62(1):64-73.
6. Fritz KS, McKean AJ, Nelson JC, et al. Analog-based free testosterone test results linked to total testosterone concentrations, not free testosterone concentrations. *Clinical chemistry*. 2008;54(3):512-6.
7. Swerdloff RS, Wang C. Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence. *Clinical chemistry*. 2008;54(3):458-60.
8. Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. *J Clin Endocrinol Metab*. 2001;86(6):2903.
9. Keevil BG, MacDonald P, Macdowall W, et al. Salivary testosterone measurement by liquid chromatography tandem mass spectrometry in adult males and females. *Ann Clin Biochem*. 2014;51(3):368-78.
10. Fiers T, Delanghe J, T'Sjoen G, et al. A critical evaluation of salivary testosterone as a method for the assessment of serum testosterone. *Steroids*. 2014;86:5-9.